Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Mar 30, 2015 BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopha...
PDF
Feb 26, 2015 BOSTON, Feb. 26, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2014, and provided an update on the company's recent activities. "ZIOPHARM has achieved remarkable progress in the last several quarters, uniting a number of technologies and d...
PDF
Feb 12, 2015 BOSTON, Feb. 12, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ...
PDF
Feb 5, 2015 BOSTON, Feb. 5, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10th, 2015 at 10:30 a.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City. To ...
PDF
Feb 3, 2015 BOSTON, Feb. 3, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it has priced its previously announced underwritten public offering of common stock consisting of 10,000,000 shares at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from this offering are expected to be approximately $87.5 mi...
PDF
Feb 2, 2015 BOSTON, Feb. 2, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to commence an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM. J.P. Morgan Securities LLC is acting as sole book-running manager for the ...
PDF
Jan 13, 2015
PDF
Jan 7, 2015 BOSTON, Jan. 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2015 at 3:30 p.m. PT at The Westin St. Francis in San Francisco, CA. To access a live audio webca...
PDF
Dec 3, 2014 BOSTON, Mass. and GERMANTOWN, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of clinical and preclinical studies from...
PDF
Oct 30, 2014 BOSTON, Oct. 30, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2014, and provided an update on the company's product development activities. "During the third quarter, we continued to execute our strategy and advance our immuno-oncology platform, includ...
PDF
Page:
1
... NextLast